Literature DB >> 31980473

Chronic intestinal pseudo-obstruction due to β2microglobulin-amyloidosis in a patient on high-flux haemodialysis.

Pieter De Mulder1,2, Kristof Cokelaere3, Wim Terryn3.   

Abstract

Dialysis-related amyloidosis (DRA) or β2microglobulin (β2m)-amyloidosis is a disorder caused by the inability to clear a protein called β2m in patients with chronic kidney disease. It results in deposition of β2m as amyloid fibrils, most commonly in bones and joints. Infrequently, visceral organs may be involved. With modern high-flux haemodialysis, DRA has become a rare disease, yet it may occur. We present a case of DRA in an 86-year-old woman. This case is particularly notable for its rare presentation as chronic intestinal pseudo-obstruction. It is of paramount importance to recognise this entity in order to reduce delay in treatment and avoid patients being frustrated not getting a diagnosis. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dialysis; gastroenterology; renal medicine

Mesh:

Substances:

Year:  2020        PMID: 31980473      PMCID: PMC7021141          DOI: 10.1136/bcr-2019-232201

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

Review 1.  Morphogenesis of joint beta 2-microglobulin amyloid deposits.

Authors:  C van Ypersele De Strihou; M Jadoul; C Garbar
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

2.  Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies.

Authors:  Maria-Eleni Roumelioti; Gregory Trietley; Thomas D Nolin; Yue-Harn Ng; Zhi Xu; Ahmed Alaini; Rocio Figueroa; Mark L Unruh; Christos P Argyropoulos
Journal:  Nephrol Dial Transplant       Date:  2018-06-01       Impact factor: 5.992

Review 3.  Abeta-2M-amyloidosis and related bone diseases.

Authors:  Junichiro James Kazama; Suguru Yamamoto; Naoki Takahashi; Yumi Ito; Hiroki Maruyama; Ichiei Narita; Fumitake Gejyo
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Visceral organ involvement and extracellular matrix changes in beta 2-microglobulin amyloidosis--a comparative study with systemic AA and AL amyloidosis.

Authors:  K Ohashi; R Takagawa; M Hara
Journal:  Virchows Arch       Date:  1997-06       Impact factor: 4.064

5.  Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010.

Authors:  Junichi Hoshino; Kunihiro Yamagata; Shinichi Nishi; Shigeru Nakai; Ikuto Masakane; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Nephrol Dial Transplant       Date:  2015-07-22       Impact factor: 5.992

6.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

Review 7.  Amyloidosis: a clinical overview.

Authors:  Bouke P C Hazenberg
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

8.  Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Authors:  Julie A Vrana; Jeffrey D Gamez; Benjamin J Madden; Jason D Theis; H Robert Bergen; Ahmet Dogan
Journal:  Blood       Date:  2009-10-01       Impact factor: 22.113

Review 9.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

10.  Mucosal gastric calcinosis in a hypocalcaemic patient.

Authors:  Demet Dincay; Kadri Atay; Ibrahim Hatemi; Nuray Kepil; Fatma Ela Keskin; Tuğçe Apaydın; Pinar Kadioglu
Journal:  Prz Gastroenterol       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.